Monte Rosa Therapeutics, Inc. (GLUE)
- Previous Close
3.8500 - Open
4.4700 - Bid 3.7600 x 100
- Ask 3.9000 x 100
- Day's Range
3.8000 - 4.5950 - 52 Week Range
3.2100 - 12.4000 - Volume
176,434 - Avg. Volume
691,739 - Market Cap (intraday)
234.967M - Beta (5Y Monthly) 1.52
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9800 - Earnings Date May 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.12
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
www.monterosatx.comRecent News: GLUE
View MorePerformance Overview: GLUE
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLUE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLUE
View MoreValuation Measures
Market Cap
236.81M
Enterprise Value
-92.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.76
Price/Book (mrq)
1.06
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-96.14%
Return on Assets (ttm)
-13.65%
Return on Equity (ttm)
-36.15%
Revenue (ttm)
75.62M
Net Income Avi to Common (ttm)
-72.7M
Diluted EPS (ttm)
-0.9800
Balance Sheet and Cash Flow
Total Cash (mrq)
372.15M
Total Debt/Equity (mrq)
19.16%
Levered Free Cash Flow (ttm)
81.97M